Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

RARE PHOTOS: Natera inc org | Rare Historical Photos

S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today

The S&P 500 cleared 7,755 and Wall Street is on course for its best week since April.

Benzinga · Aug 7

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test.

Benzinga · Aug 29, 2025

This Diagnostic Testing Company Down 60% - Time to Buy?

Despite witnessing double-digit revenue growth in the last reported quarter Natera Inc. (NTRA) stock has plunged nearly 60% year-to-date. So, let’s evaluate if it is worth buying the stock now. Read on.

StockNews.com · Jun 29, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…

Benzinga · May 6, 2022

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was healthy. FDA issues warning on possible false results from noninvasive prenatal screening tests. The agency noted that these tests, also known as…

Benzinga · Apr 20, 2022

So What's Happening With Natera Shares?

Natera Inc (NASDAQ: NTRA) shares are trading lower by 31.2% at $37.66 after Hindenburg Research issued a short report on the stock.

Benzinga · Mar 9, 2022

3 Reasons Why This Natera Analyst Says The Selloff Is Overdone

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company following a Hindenburg Research short

Benzinga · Mar 9, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

People

William Blair

55 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Agilent Technologies Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.